GlassScriptPhysician profile
Robert H Bush
NPI 1952302481
$1,621.50
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $774 · 2021: $101.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $354.46 | 2019-2020 | |
| Novo Nordisk INC | $282.53 | 2019-2021 | |
| Pfizer INC. | $132.81 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $119.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $112.76 | 2020 | |
| Allergan, INC. | $86.51 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $78.49 | 2019-2020 | |
| Amgen INC. | $75.69 | 2019-2020 | |
| Abbvie INC. | $71.22 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.55 | 2019 | |
| Merck Sharp & Dohme LLC | $50.05 | 2019-2020 | |
| Lilly USA, LLC | $33.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.48 | 2019-2020 | |
| Eisai INC. | $29.69 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.69 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $18.76 | 2019 | |
| Glaxosmithkline, LLC. | $15.47 | 2019 | |
| Genentech USA, INC. | $13.81 | 2019 | |
| Dexcom, INC. | $12.38 | 2021 | |
| Aytu Biopharma, INC. | $11.99 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.